Keynote webinar | Spotlight on antibody–drug conjugates in cancer
Live event recorded: Monday 19th February, 2024
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types.
Learn about the mechanism of action of ADCs, the key clinical trials in the breast and lung cancer settings, as well as current challenges and future directions in this expert-led symposium.
You must have an account and be logged in to access the recording of this webinar. The on-demand version is not accredited.
No account yet? Register here for free
Agenda
Antibody–drug conjugates in breast cancer
Dr. Véronique Diéras
Achievements and challenges for antibody–drug conjugates in advanced NSCLC
Prof. Fabrice Barlesi
Panel discussion with both experts
Faculty
Dr. Véronique Diéras
Head, Breast Cancer Group, Centre Eugène Marquis, Rennes, France
Prof. Fabrice Barlesi
Chief Executive Officer, Gustave Roussy, Villejuif, France
Learning objectives
After this webinar, participants will have an understanding of:
- The mechanism of action of ADCs
- The latest efficacy data for key ADCs in breast and lung cancer
- The unique side effects of these agents, and how best to manage them
Faculty information and disclosures
Dr. Véronique Diéras
Head, Breast Cancer Group, Centre Eugène Marquis, Rennes, France
Read more »
Disclosures
- Travel expenses: Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo
- Honoraria: Consultancy/Advisory boards: Roche/Genentech, Novartis, Lilly, Pfizer, AstraZeneca, AbbVie, MSD, Daiichi Sankyo, Seattle Genetics, Gilead, Eisai, Pierre Fabre Oncologie
Honoraria: Symposia: Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo
Prof. Fabrice Barlesi
Chief Executive Officer, Gustave Roussy, Villejuif, France
Read more »
Disclosures
- Personal financial interests: None (since August 2021)
- Institutional financial interests: Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis and Takeda
- Non-financial interests: Principal Investigator for Astra-Zeneca, BMS, Innate Pharma, Merck, Mirati, Pierre Fabre and F. Hoffmann-La Roche, Ltd, sponsored trials (or ISR)
Dr. Shreeya Nanda
Senior Clinical Content Manager, Springer Medicine, Springer Healthcare, London, United Kingdom
Disclosures
Dr. Jane Godsland
Clinical Director, Springer Medicine, Springer Healthcare, London, United Kingdom
Disclosures
